Genmab A/S - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Genmab A/S - Product Pipeline Review - 2016', provides an overview of the Genmab A/S's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Genmab A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Genmab A/S - The report provides overview of Genmab A/S including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Genmab A/S's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Genmab A/S's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Genmab A/S's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Genmab A/S - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Genmab A/S's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Content 2 List of Tables 4 List of Figures 4 Genmab A/S Snapshot 5 Genmab A/S Overview 5 Key Information 5 Key Facts 5 Genmab A/S - Research and Development Overview 6 Key Therapeutic Areas 6 Genmab A/S - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 Genmab A/S - Pipeline Products Glance 15 Genmab A/S - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Genmab A/S - Early Stage Pipeline Products 17 Preclinical Products/Combination Treatment Modalities 17 Genmab A/S - Drug Profiles 18 teprotumumab 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 tisotumab vedotin 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 HuMax-AXL-ADC 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 IDD-004 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Monoclonal Antibody 1 for Central Nervous System Disorders 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Monoclonal Antibody 2 for Central Nervous System Disorders 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Monoclonal Antibody 3 for Central Nervous System Disorders 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Mononclonal Antibody 1 for Oncology 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Mononclonal Antibody 2 for Oncology 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Mononclonal Antibody Conjugate for Oncology 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Genmab A/S - Pipeline Analysis 31 Genmab A/S - Pipeline Products by Target 31 Genmab A/S - Pipeline Products by Route of Administration 32 Genmab A/S - Pipeline Products by Molecule Type 33 Genmab A/S - Pipeline Products by Mechanism of Action 34 Genmab A/S - Recent Pipeline Updates 35 Genmab A/S - Dormant Projects 37 Genmab A/S - Discontinued Pipeline Products 38 Discontinued Pipeline Product Profiles 38 HuMax-CD74-ADC 38 teprotumumab 38 Genmab A/S - Company Statement 39 Genmab A/S - Locations And Subsidiaries 41 Head Office 41 Other Locations & Subsidiaries 41 Appendix 42 Methodology 42 Coverage 42 Secondary Research 42 Primary Research 42 Expert Panel Validation 42 Contact Us 42 Disclaimer 43
List of Tables
Genmab A/S, Key Information 5 Genmab A/S, Key Facts 5 Genmab A/S - Pipeline by Indication, 2016 7 Genmab A/S - Pipeline by Stage of Development, 2016 9 Genmab A/S - Monotherapy Products in Pipeline, 2016 10 Genmab A/S - Partnered Products in Pipeline, 2016 11 Genmab A/S - Partnered Products/ Combination Treatment Modalities, 2016 12 Genmab A/S - Out-Licensed Products in Pipeline, 2016 13 Genmab A/S - Out-Licensed Products/ Combination Treatment Modalities, 2016 14 Genmab A/S - Phase II, 2016 15 Genmab A/S - Phase I, 2016 16 Genmab A/S - Preclinical, 2016 17 Genmab A/S - Pipeline by Target, 2016 31 Genmab A/S - Pipeline by Route of Administration, 2016 32 Genmab A/S - Pipeline by Molecule Type, 2016 33 Genmab A/S - Pipeline Products by Mechanism of Action, 2016 34 Genmab A/S - Recent Pipeline Updates, 2016 35 Genmab A/S - Dormant Developmental Projects,2016 37 Genmab A/S - Discontinued Pipeline Products, 2016 38 Genmab A/S, Subsidiaries 41
List of Figures
Genmab A/S - Pipeline by Top 10 Indication, 2016 7 Genmab A/S - Pipeline by Stage of Development, 2016 9 Genmab A/S - Monotherapy Products in Pipeline, 2016 10 Genmab A/S - Partnered Products in Pipeline, 2016 11 Genmab A/S - Out-Licensed Products in Pipeline, 2016 13 Genmab A/S - Pipeline by Target, 2016 31 Genmab A/S - Pipeline by Route of Administration, 2016 32 Genmab A/S - Pipeline by Molecule Type, 2016 33 Genmab A/S - Pipeline Products by Mechanism of Action, 2016 34
Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global demRead More...
Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the markeRead More...
Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to driRead More...
Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demandRead More...
Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expectedRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.